Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2017 | Original Article

Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma

Authors: Hui Zhang, Yan Guo, Yongsheng Song, Chao Shang

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2017

Abstract

Purpose

Bladder cancer is the most general malignant cancer in genitourinary system, more than 90% of BCs are bladder transitional cell carcinomas (BTCC). This study aimed to investigate the clinical significance of growth arrest-specific 5 (GAS5) gene and its regulatory effects of malignant proliferation and chemotherapy resistance to doxorubicin in BTCC cells.

Methods

The expression of GAS5 was detected by quantitative real-time PCR. Statistical analysis was used to determine the relationship between GAS5 expression and clinical features and the prognostic value of GAS5 for disease free survival. MTT assay was used to detect cell proliferation ability and chemosensitivity. Dual-color flow cytometric method was used to detect cell apoptosis. The expression of Bcl-2 protein was examined by western blot.

Results

In this study, we found that GAS5 low-expressed in BTCC tissues and cells, and its low expression level had positive correlation with higher pathological grades of BTCC. Moreover, GAS5 was a prognostic biomarker of disease free survival for BTCC patients. GAS5 over-expression could inhibit cell proliferation of BTCC J82 and T24 cells significantly. The IC50 to doxorubicin in T24/DOX cells (resistance to doxorubicin) presented a conspicuous depression, GAS5 enhancement reduced the chemotherapy resistance to doxorubicin. GAS5 over-expression promoted apoptosis induced by doxorubicin in T24/DOX cells, and depressed the expression of anti-apoptosis protein Bcl-2. The results indicated that GAS5 regulated the chemotherapy resistance to doxorubicin via Bcl2 partly.

Conclusions

In summary, lncRNA GAS5 was a prognostic biomarker of disease free survival in BTCC patients, and acted as a tumor-suppressing gene to inhibit malignant proliferation and resistance to doxorubicin in BTCC cells. LncRNA GAS5 might be a novel potential therapeutic target for BTCC.

Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N (2007) Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 25:285–295CrossRefPubMed

Hassen W, Droller MJ (2000) Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol 10:291–299CrossRefPubMed

Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P (2014) Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. Cancer Chemother Pharmacol 73(3):503–509CrossRefPubMed

Shang C, Guo Y, Zhang J, Huang B (2016) Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemother Pharmacol 77(5):1061–1067CrossRefPubMed

Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, Weng H, Shu YJ, Liu TY, Jiang L, Cao Y, Bao RF, Mu JS, Tan ZJ, Tao F, Liu YB (2014) MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther 15(6):806–814CrossRefPubMedPubMedCentral

Carrieri C, Forrest AR, Santoro C, Persichetti F, Carninci P, Zucchelli S, Gustincich S (2015) Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells’ differentiation in vitro and in neurochemical models of Parkinson’s disease. Front Cell Neurosci 9:114CrossRefPubMedPubMedCentral

Modali SD, Parekh VI, Kebebew E, Agarwal SK (2015) Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 29(2):224–237CrossRefPubMedPubMedCentral

Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, Zhou L, Zhou C, Yuan Q, Yang M (2015) Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration and invasion of esophageal squamous cell carcinoma cells. J Biol Chem 290(7):3925–3935CrossRefPubMed

Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q, Zhang J (2016) Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumor Biol 37(2):2691–2702CrossRef

10.

Gao J, Liu M, Zou Y, Mao M, Shen T, Zhang C, Song S, Sun M, Zhang S, Wang B, Zhu D, Li P (2015) Long non-coding RNA growth arrest-specific transcript 5 is involved in ovarian cancer cell apoptosis through the mitochondria-mediated apoptosis pathway. Oncol Rep 34(6):3212–3221PubMed

11.

Guo X, Deng K, Wang H, Xia J, Shan T, Liang Z, Yao L, Jin S (2015) GAS5 inhibits gastric cancer cell proliferation partly by modulating CDK6. Oncol Res Treat 38(7–8):362–366CrossRefPubMed

12.

Yu X, Li Z (2015) Long non-coding RNA growth arrest-specific transcript 5 in tumor biology. Oncol Lett 10(4):1953–1958PubMedPubMedCentral

13.

Liu Z, Wang W, Jiang J, Bao E, Xu D, Zeng Y, Tao L, Qiu J (2013) Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE 8(9):e73991CrossRefPubMedPubMedCentral

14.

Song J, Lee JE (2015) ASK1 modulates the expression of microRNA Let7A in microglia under high glucose in vitro condition. Front Cell Neurosci 9:198PubMedPubMedCentral

15.

Yiwei T, Hua H, Hui G, Mao M, Xiang L (2015) HOTAIR Interacting with MAPK1 regulates ovarian cancer skov3 cell proliferation, migration, and invasion. Med Sci Monit 21:1856–1863CrossRefPubMedPubMedCentral

16.

Shang C, Guo Y, Hong Y, Xue YX (2016) Long non-coding RNA TUSC7, a target of miR-23b, plays tumor-suppressing roles in human gliomas. Front Cell Neurosci 10:235CrossRefPubMedPubMedCentral

17.

Zhang J, Yao T, Wang Y, Yu J, Liu Y, Lin Z (2016) Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther 17(1):104–113CrossRefPubMed

18.

Zhan Y, Liu Y, Wang C, Lin J, Chen M, Chen X, Zhuang C, Liu L, Xu W, Zhou Q, Sun X, Zhang Q, Zhao G, Huang W (2016) Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget 7(13):16038–16048PubMedPubMedCentral

19.

Zhu Y, Dai B, Zhang H, Shi G, Shen Y, Ye D (2016) Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. Cancer Lett 380(2):369–374CrossRefPubMed

20.

Chen T, Xie W, Xie L, Sun Y, Zhang Y, Shen Z, Sha N, Xu H, Wu Z, Hu H, Wu C (2015) Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer. Biochem Biophys Res Commun 468(4):666–670CrossRefPubMed

21.

Zhao XL, Zhao ZH, Xu WC, Hou JQ, Du XY (2015) Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Int J Clin Exp Pathol 8(2):1954–1960PubMedPubMedCentral

22.

Cao Q, Wang N, Qi J, Gu Z, Shen H (2016) Long non-coding RNA-GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (C–C motif) ligand 1 expression. Mol Med Rep 13(1):27–34PubMed

23.

Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W, Wei Q (2016) Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7(19):27778–27786PubMedPubMedCentral

Title: Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma
Authors: Hui Zhang
Yan Guo
Yongsheng Song
Chao Shang
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3194-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Population pharmacokinetics of lenalidomide in multiple myeloma patients

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma

Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer